Baseline Biomarker Check (BBC) Study
Predicting treatment response in people experiencing a first episode of psychosis: using biological markers to improve drug selection and treatment.
King’s College London are launching a new clinical study called the Baseline Biomarker Check study. This website describes the aims of the study, who we wish to take part, and what the study involves. This information should help you to understand whether you may be interested in or eligible to take part in the BBC study
About the study
The aim of the Baseline Biomarker Check (BBC) study is to explore whether biological markers (so called ‘biomarkers’) can help us to predict how well a patient with psychosis may respond to a medication.
We plan to develop a tool to predict treatment outcome for people experiencing their first episode of psychosis.
The study is a collaboration between the Department of Psychosis Studies in the Institute of Psychiatry, Psychology & Neuroscience at King's College London and the South London and Maudsley NHS Foundation Trust.
We are currently looking to recruit patients experiencing a first episode of psychosis as well as individuals who have never experienced psychosis.